ArticleJAMA network open2021

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.

Xin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.